Skip to main navigation Skip to search Skip to main content

Passive immunotherapies for Alzheimer's disease

Research output: Contribution to journal › Review article › peer-review

Abstract

After decades of arduous work, considerable progress has been made in developing a new generation of treatments that may ease symptoms of Alzheimer's disease and might even stop its progression. Several compounds are in mid- and late-stage clinical trials, and the first new drugs could be marketed in a few years. The drugs could be used to keep the disease in check, giving patients the prospect of living relatively normal lives.

Original languageEnglish
Pages (from-to)185-189
Number of pages5
JournalDrug Discovery Today: Therapeutic Strategies
Volume5
Issue number3
DOIs
StatePublished - Sep 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Passive immunotherapies for Alzheimer's disease'. Together they form a unique fingerprint.

Cite this